CompoundAtlas
Sign in

LGD-4033

67
evidence score
sarm
Research Only
184 studies
LigandrolVK5211LGD4033

LGD-4033 (Ligandrol) is a potent oral SARM with Phase I safety data and Phase II trial data for hip fracture recovery (VK5211, 1–2mg/day). Significantly more anabolic than ostarine at milligram doses — 1mg/day in Phase I produced ~1.2kg lean mass gain. Widely used in fitness communities for bulking. Causes robust testosterone suppression even at low doses. Not approved for human use. WADA-prohibited. Among the most detected substances in athlete doping cases.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

Phase II

Last Sync

Feb 19, 2026

Last Reviewed

Not reviewed yet

Dosing

Typical
10 mg
2 mgRange20 mg
FrequencyOnce daily oral

Set height & weight in Settings to see your dose.

Pharmacology

Half-life24–36 hours
Onset1–2 weeks for noticeable strength; 4–6 weeks for body composition
DurationSuppression persists 4–6 weeks post-cycle
Routes
oral

Evidence Score

67
Level B — Moderate
184 studies indexed · 1 meta-analysis
Scoring Factors
Volume(24%)~45/100
Quality(24%)~44/100
Sample Size(12%)~88/100
Consistency(14%)~88/100
Replication(8%)~88/100
Recency(18%)~88/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

LGD-4033 is currently categorized as a sarm compound.

Evidence is moderate (67/100): promising signal from 184 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

High-affinity selective AR agonist; near-complete receptor occupancy at low doses produces significant muscle anabolism with moderate bone activation

Practical Context

Strongest current signals

  • Level A: Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review.
  • Level B: Development and preliminary testing of a secure large language model-based chatbot for brief alcohol counseling in young adults.
  • Level C: Lipid polymorphism of plant thylakoid membranes. The dynamic exchange model - facts and hypotheses.

Elevated caution signals

1 severe/high side effect flag

Compound Profile